Literature DB >> 11392447

Role of formulation vehicles in taxane pharmacology.

L van Zuylen1, J Verweij, A Sparreboom.   

Abstract

The non-ionic surfactants Cremophor EL (CrEL) and Tween 80, both used as formulation vehicles of many (anticancer) agents including paclitaxel and docetaxel, are not physiological inert compounds. We describe their biological properties, especially the toxic side effects, and their pharmacological properties, such as modulation of P-glycoprotein activity. In detail, we discuss their influence on the disposition of the solubilized drugs, with focus on CrEL and paclitaxel, and of concomitantly administered drugs. The ability of the surfactants to form micelles in aqueous solution as well as biological fluids (e.g. plasma) appears to be of great importance with respect to the pharmacokinetic behavior of the formulated drugs. Due to drug entrapment in the micelles, plasma concentrations and clearance of free drug change significant leading to alteration in pharmacodynamic characteristics. We conclude with some perspectives related to further investigation and development of alternative methods of administration.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11392447     DOI: 10.1023/a:1010618632738

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN: 0167-6997            Impact factor:   3.850


  130 in total

1.  Combined doxorubicin and paclitaxel in advanced breast cancer: effective and cardiotoxic.

Authors:  J Gehl; M Boesgaard; T Paaske; B Vittrup Jensen; P Dombernowsky
Journal:  Ann Oncol       Date:  1996-09       Impact factor: 32.976

2.  Complement activation by Cremophor EL as a possible contributor to hypersensitivity to paclitaxel: an in vitro study.

Authors:  J Szebeni; F M Muggia; C R Alving
Journal:  J Natl Cancer Inst       Date:  1998-02-18       Impact factor: 13.506

3.  Cholestatic effects of cyclosporine in the rat.

Authors:  F K Chan; E A Shaffer
Journal:  Transplantation       Date:  1997-06-15       Impact factor: 4.939

4.  Disposition of [G-(3)H]paclitaxel and cremophor EL in a patient with severely impaired renal function.

Authors:  H Gelderblom; J Verweij; E Brouwer; M Pillay; P de Bruijn; K Nooter; G Stoter; A Sparreboom
Journal:  Drug Metab Dispos       Date:  1999-11       Impact factor: 3.922

5.  Coadministration of oral cyclosporin A enables oral therapy with paclitaxel.

Authors:  J M Meerum Terwogt; M M Malingré; J H Beijnen; W W ten Bokkel Huinink; H Rosing; F J Koopman; O van Tellingen; M Swart; J H Schellens
Journal:  Clin Cancer Res       Date:  1999-11       Impact factor: 12.531

6.  Plasma concentrations of polysorbate 80 measured in patients following administration of docetaxel or etoposide.

Authors:  L K Webster; M E Linsenmeyer; D Rischin; M E Urch; D M Woodcock; M J Millward
Journal:  Cancer Chemother Pharmacol       Date:  1997       Impact factor: 3.333

7.  Allergic reactions to teniposide in patients with neuroblastoma and lymphoid malignancies.

Authors:  F A Hayes; M Abromowitch; A A Green
Journal:  Cancer Treat Rep       Date:  1985-04

8.  Hypersensitivity reactions from taxol.

Authors:  R B Weiss; R C Donehower; P H Wiernik; T Ohnuma; R J Gralla; D L Trump; J R Baker; D A Van Echo; D D Von Hoff; B Leyland-Jones
Journal:  J Clin Oncol       Date:  1990-07       Impact factor: 44.544

9.  [Study for modifying activity of solvents on antitumor activity of paclitaxel].

Authors:  S Fujimoto
Journal:  Gan To Kagaku Ryoho       Date:  1994-04

10.  Current sample handling methods for measurement of platinum-DNA adducts in leucocytes in man lead to discrepant results in DNA adduct levels and DNA repair.

Authors:  J Ma; J Verweij; A S Planting; M de Boer-Dennert; H E van Ingen; M E van der Burg; G Stoter; J H Schellens
Journal:  Br J Cancer       Date:  1995-03       Impact factor: 7.640

View more
  59 in total

Review 1.  Advances in the use of tocols as drug delivery vehicles.

Authors:  Panayiotis P Constantinides; Jihong Han; Stanley S Davis
Journal:  Pharm Res       Date:  2006-01-25       Impact factor: 4.200

2.  Engineering erythrocytes as a novel carrier for the targeted delivery of the anticancer drug paclitaxel.

Authors:  Gamaleldin I Harisa; Mohamed F Ibrahim; Fars Alanazi; Gamal A Shazly
Journal:  Saudi Pharm J       Date:  2013-01-07       Impact factor: 4.330

3.  Development and characterization of resveratrol nanoemulsions carrying dual-imaging agents.

Authors:  Michele Herneisey; Jonathan Williams; Janja Mirtic; Lu Liu; Sneha Potdar; Christina Bagia; Jane E Cavanaugh; Jelena M Janjic
Journal:  Ther Deliv       Date:  2016-11-11

4.  Anticancer activity of Noscapine, an opioid alkaloid in combination with Cisplatin in human non-small cell lung cancer.

Authors:  Mahavir Chougule; Apurva R Patel; Pratik Sachdeva; Tanise Jackson; Mandip Singh
Journal:  Lung Cancer       Date:  2010-07-31       Impact factor: 5.705

5.  A phase I study of liposomal-encapsulated docetaxel (LE-DT) in patients with advanced solid tumor malignancies.

Authors:  John F Deeken; Rebecca Slack; Glen J Weiss; Ramesh K Ramanathan; Michael J Pishvaian; Jimmy Hwang; Karen Lewandowski; Deepa Subramaniam; Aiwu Ruth He; Ion Cotarla; Aquilur Rahman; John L Marshall
Journal:  Cancer Chemother Pharmacol       Date:  2012-12-30       Impact factor: 3.333

6.  Paclitaxel in a novel formulation containing less Cremophor EL as first-line therapy for advanced breast cancer: a phase II trial.

Authors:  Ta-Chung Chao; Zyting Chu; Ling-Ming Tseng; Tzeon-Jye Chiou; Ruey-Kuen Hsieh; Wei-Shu Wang; Chueh-Chuan Yen; Muh-Hwa Yang; Liang-Tsai Hsiao; Jin-Hwang Liu; Po-Min Chen
Journal:  Invest New Drugs       Date:  2005-03       Impact factor: 3.850

7.  New cutaneous toxicities with generic docetaxel: are the excipients guilty?

Authors:  Margarita Garrido-Siles; Jose Javier Arenas-Villafranca; Elísabeth Pérez-Ruiz; M Francisca de Linares Fernández; Begoña Tortajada; Francisco Rivas-Ruiz; Vicente Faus; Antonio Rueda
Journal:  Support Care Cancer       Date:  2014-12-10       Impact factor: 3.603

Review 8.  Pharmacological effects of formulation vehicles : implications for cancer chemotherapy.

Authors:  Albert J ten Tije; Jaap Verweij; Walter J Loos; Alex Sparreboom
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

9.  Targeted delivery of albumin bound paclitaxel in the treatment of advanced breast cancer.

Authors:  Francesco Di Costanzo; Silvia Gasperoni; Virginia Rotella; Federica Di Costanzo
Journal:  Onco Targets Ther       Date:  2009-02-18       Impact factor: 4.147

Review 10.  Albumin-bound formulation of paclitaxel (Abraxane ABI-007) in the treatment of breast cancer.

Authors:  Evelina Miele; Gian Paolo Spinelli; Ermanno Miele; Federica Tomao; Silverio Tomao
Journal:  Int J Nanomedicine       Date:  2009-04-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.